JAK inhibitors in rheumatology
JAK inhibitors in rheumatology
复制标题
DOI：
10.1080/25785826.2023.2172808
复制
发表时间：
2023-02
影响因子：
4.4
通讯作者：
K. Yamaoka;K. Oku
中科院分区：
文献类型：
--
作者：
K. Yamaoka;K. Oku
JAKis是一组作用机制与生物制剂不同的药物，在风湿病领域应用最快。JAK是一种在细胞质中被多种细胞因子和激素激活的蛋白激酶，参与炎症病理过程。JAK在多种疾病中均有表达，提示JAK抑制剂在多种免疫介导性炎症性疾病中的作用。基于JAKis的治疗效果，一些不同的风湿病的临床试验正在进行中，这与生物制品的疗效相当。本文将从有效性和安全性两个方面综述JAKI治疗风湿性疾病的现状，并扩展到未来在罕见疾病的临床应用。
Abstract Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating the utility of JAK inhibitors in a wide variety of immune-mediated inflammatory diseases. Clinical trials are underway for a number of different rheumatic diseases based on the therapeutic efficacy of JAKis, which is comparable to that of biologics. This article will review the current status of JAKis for rheumatic diseases in terms of efficacy and safety and extend to future clinical applications for rare diseases.